

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

50-795

MICROBIOLOGY REVIEW

DIVISION OF ANTI-INFECTIVE DRUG PRODUCTS (HFD-520)
Clinical Microbiology Review of Labeling on NDA 50-795

NDA#: 50-795 **REVIEW #:** 1 **DATE COMPLETED:** 03/04/05

<u>SUBMISSION/TYPE</u>	<u>DOCUMENT DATE</u>	<u>CDER DATE</u>	<u>ASSIGNED DATE</u>
50-795 / Original	04/05/04	04/07/04	04/05/04

NAME & ADDRESS OF APPLICANT:

F H Faulding & Co., Ltd. (t/a* Mayne Pharma International)
1538 Main North Road
Salisbury South, South Australia 5106, Australia

* t/a = "trading as"

AUTHORIZED U.S. AGENT NAME & ADDRESS:

Warner Chilcott, Inc.
Rockaway 80 Corporate Center
100 Enterprise Drive, Suite 280
Rockaway, NJ 07866
Tel: (973) 442-3200 / FAX: (973) 442.3280

CONTACT PERSONS:

Alvin D. Howard
Vice President, Regulatory Affairs
Tel: (973) 442-3233

or

David Haenick, Ph.D.
Manager, Regulatory Affairs
Tel: (973) 442-3364

SUBMISSIONS REVIEWED:

This is an original NDA for a **new** dosage form, **tablet**, for the Applicant's existing marketed drug product, DORYX® (coated doxycycline hyclate pellets), 75 mg and 100 mg Capsules, respectively.

DRUG PRODUCT NAME:

Proprietary:	DORYX® (coated doxycycline hyclate pellets) Tablets
Non-Proprietary/USAN:	doxycycline hyclate
Code Name:	N/A
CAS No:	CAS-24390-14-5 / CAS-564-25-0 (doxycycline)

CHEMICAL NAME, STRUCTURE, MOLECULAR FORMULA, MOL. W.T.:

doxycycline hyclate

Chemical Name/Structure	=	See 2000 USAN (page 250)
Molecular Formula	=	(C ₂₂ H ₂₄ N ₂ O ₈ HCl) ₂ ·C ₂ H ₆ O·H ₂ O
Molecular Weight	=	_____

DOSAGE FORM: Tablet

STRENGTH:

Each capsule contains doxycycline hyclate equivalent to 75 mg or 100 mg of doxycycline.

ROUTE OF ADMINISTRATION: Oral

DISPENSED: x Rx

PHARMACOLOGICAL CATEGORY/INDICATION:

Tetracycline antibiotic (synthetically derived from oxytetracycline);

The indications listed for doxycycline (as doxycycline hyclate) are too numerous to mention. Therefore, refer to NDA 50-582, approved labeling on DORYX® (coated doxycycline hyclate pellets), 75 mg and 100 mg Capsules®, **INDICATIONS AND USAGE** section.

RELATED DOCUMENTS:

NDA 50-582, DORYX® (coated doxycycline hyclate pellets), 75 mg (approved 08/31/01) and 100 mg (approved 07/22/85) Capsules®.
ANDA 62-653, DORYX® (coated doxycycline hyclate pellets), 100 mg Capsules®.

REMARKS:

This is a Clinical Microbiology Review on the proposed labeling for a new dosage form: DORYX® (coated doxycycline hyclate pellets) Tablets. DAIDP (HFD-520) and the Applicant concurred at a pre-NDA meeting that the Doryx® Tablet labeling complies with the content of the approved Vibramycin labeling. Therefore, all the labeling for the proposed Doryx® Tablet, i.e., the Prescribing Information for the marketplace and the Prescribing information for the bulk supplies, are to be similar to the "approved" Vibramycin, #69-1680-32-9, revised September 2003.

Again, this is an original NDA for a **new** dosage form, a **tablet**, for their existing marketed drug product, DORYX® (coated doxycycline hyclate pellets), 75 mg and 100 mg capsules. The DORYX® 100 mg Capsules are marketed under approved NDA 50-582 and ANDA 62-653. The DORYX® 75 mg Capsules are marketed under NDA 50-582.

In addition, the Applicant submitted a food effect study and dissolution data for bioequivalency with its FDA "approved" capsule. This is to support and demonstrate that the tablet form is bioequivalent to the capsule form (and therefore, also to the approved Vibramycin).

CONCLUSIONS:

From the microbiological perspective, an "approval" letter should be issued to the Applicant, after negotiation of the most current revised "draft" labeling, March 2004, W0112G030. This includes all the below Agency's minor content and editorial labeling recommendations in the **MICROBIOLOGY** section and **Susceptibility Test Methods** subsection of the Package Insert. The revisions, changes, and other informational comments are also found on pages 3 to 9 and finalized on pages 10 to 13, respectively.

Clinical Microbiology Reviewer's Comments:


9 Page(s) Withheld

 § 552(b)(4) Trade Secret / Confidential

 § 552(b)(5) Deliberative Process

✓ § 552(b)(5) Draft Labeling

[



]

REFERENCES

1. National Committee for Clinical Laboratory Standards, *Performance Standards for Antimicrobial Disk Susceptibility Tests*, Fourth Edition. Approved Standard NCCLS Document M2-A4, Vol. 10, No.7 NCCLS Villanova, PA, April 1990.
2. National Committee for Clinical Laboratory Standards, *Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically*, Second Edition. Approved Standard NCCLS Document M7-A2, Vol. 10, No. 8 NCCLS, Villanova, PA, April 1990.

NDA 50-795

Page 13 OF 13

F H Faulding & Company

DORYX® (coated doxycycline hyclate pellets) Tablets, 75 and 100 mg

NOTE: It is recommended that the Division notify the innovator to make current and update the "doxycycline" labeling using the current **REFERENCES** on page 9. In addition, the innovator is to be provided the **DRAFT – "Guidance for Industry - Microbiological Data for Antibacterial Drug Products — Development, Analysis, and Presentation"** document for making current and updating the microbiology labeling, format, and content.

Harold V. Silver
Clinical Microbiology Reviewer
DAIDP/HFD-520

cc: Orig. NDA 50-795
HFD-520/TLMO/J.Alexander
HFD-520/MO/CCooper
HFD-520/Bio-Pharm/JTworzyanski
HFD-520/ProjMgr/JMilstein
HFD-520/ClinMicroRewHVS
Filename: N50795-HVS-FIN
APPROVAL

Concurrence Only:
HFD-520/ATLMicro/FMarsik
Finalized 20 Apr 05 FJM
HFD-520/DepDivDir/L.Gavrilovich

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Harold Silver
4/20/05 03:46:30 PM
MICROBIOLOGIST

Please sign off on Clinical Microbiology Review on labeling
for new dosage form for F H Faulding's
NDA 50-795, DORYX (coated doxycycline hyclate pellets) Tablets.

Frederic Marsik
4/20/05 04:01:03 PM
MICROBIOLOGIST

Lillian Gavrilovich
4/20/05 06:58:54 PM
MEDICAL OFFICER